Abstract: The present disclosure relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, which can be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid.

Abstract: Disclosed is a method for preparing an N-acetyl-D-galactosamine tripolymer precursor. In the preparation of the tripolymer precursor, a compound 4 is prepared by the following steps: adding a compound 3, a 4? molecular sieve powder, and a reaction solvent into a reactor; inflating and changing protective gas for 3 times; stirring; firstly adding an enol, followed by slowly dropping trimethylsilyl trifluoromethanesulfonate; after a reaction, quenching the reaction with an alkali solution; and performing extraction, separating liquid, washing, drying, filtration, etc., so as to obtain the compound 4. According to the present disclosure, the problems of various production processes, more times of column chromatography for purification of products accompanied by lower yields in the prior art are solved.

Abstract: The invention belongs to the field of biotechnology, and relates to an allogeneic B cell vaccine against various human-susceptible viruses and a preparation method therefor. The vaccine has anti-tumor and/or anti-viral preventive and/or therapeutic effects. Specifically, the present invention provides a B cell composition, wherein comprising an allogeneic B cell and a virus antigen, the B cell composition is irradiated with a certain dose of ionizing irradiation. The present invention also provides a B cell vaccine, comprising the above B cell composition. The invention also provides a preparation method for the B cell vaccine and a method and system for improving the antigen presentation ability of the B cell.

Abstract: The present disclosure relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, which can be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid.

Abstract: The disclosure in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the disclosure relates to gene transfer methods using the recombinant adeno-associated viruses. In some aspects, the disclosure relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.

Abstract: Provided are a binding protein targeting HER2, a preparation method and use thereof. The binding protein includes the following amino acid sequence (a): NDEMRX1TYW X2IALF X3 X4ML X5N X6X7KR X8 X9IR X10LYDDP X11X12A X13 X14LEX15 X16A X17LEA X18 X19 X20. The binding protein can bind to HER2 and has an excellent affinity with HER2. A radionuclide molecular imaging probe may be prepared by means of nuclide labeling, and it can be used in the molecular imaging diagnosis and improve the tumor imaging diagnosis to a molecular level of specific expression of tumor cells, and the HER2 expression in possible tumor lesions in vivo can be monitored in real time before a treatment scheme is determined or in the process of monitoring a medicament treatment progress.

Abstract: The present invention belongs to the field of biological medicine, particularly to a novel tumor vaccine. In order to solve the problem in the art that no technical scheme is available for generating lasting and high-effective anti-tumor immune responses, the present invention provides a tumor vaccine mainly containing a complex as a main active ingredient, wherein the complex is formed by nucleic acid, especially replicable nucleic acid not expressing exogenous gene, and cationic biomaterial. The nucleic acid and the cationic biomaterial in the tumor vaccine according to the present invention have synergistic interactions on direct killing of tumor cells, and induction of the innate immune response and adaptive immune response of body against tumor. In addition, the prepared tumor vaccine has simple drug component and is easy to produce and maintain quality control. The tumor vaccine has a good prospect for application.

Abstract: The present invention relates to the anti-SARS-CoV-2-infection protein and vaccine, and belongs to the field of medicine. Due to the lack of efficient drugs for SARS-CoV-2 infection prevention and treatment in the prior art, the present invention provides an anti-SARS-CoV-2-infection protein, which contains a domain that binds with the angiotensin-converting enzyme 2 (ACE2) receptor as contained in the SARS-CoV-2 S protein. One the other hand, the present invention also provides a vaccine for SARS-CoV-2 infection prevention and/or treatment, which comprises the anti-SARS-CoV-2-infection protein as well as the pharmaceutically acceptable excipient or auxiliary ingredient. The present invention mainly induces the production of antibodies in the body for immunoreaction and blocks the binding the SARS-CoV-2 S protein and the ACE2 receptor of the host cell, thus helping the host to fight against the corona virus infection.

Abstract: The present disclosure relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, which can be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid.

Abstract: Aspects of the disclosure relate to compositions and methods for delivering a transgene (e.g., a transgene encoding one or more gene products) to a target cell. The disclosure is based, in part, on adeno-associated virus (AAV) capsid protein variants characterized by tropisms for certain cell types (e.g., neurons, muscle cells, bone cells, heart cells, etc.). In some embodiments, recombinant A A Vs (rAAVs) comprising the capsid protein variants (e.g., AAVv66, SEQ ID NO: 1) are more efficiently packaged than rAAVs having certain wild-type AAV capsid proteins. Methods of delivering an rAAV comprising the AAV capsid protein variants are also described by the disclosure.

Abstract: Disclosed are a tumor biomarker and application thereof, and a tumor detection kit. Patients suffering from non-small cell lung cancer, containing an EML4-ALK or SLC34A2-ROS1 fusion gene, have a specific circular RNA in blood. The base sequences of the circular RNA are represented by SEQ ID NOS. 1-6. The circular RNA is associated with non-small cell lung cancer, stably and constantly exists in plasma samples, and has high specificity and effectiveness, and thus can be used as a biomarker for tumor detection. Reagents such as primers and probes for detecting the circular RNA can be used for preparing the tumor detection kit.

Abstract: The disclosure in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the disclosure relates to gene transfer methods using the recombinant adeno-associated viruses. In some aspects, the disclosure relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.

Abstract: The present invention relates to a use of a compound represented by formula (I) and a pharmaceutically acceptable salt thereof in the field of pharmaceutics, and in particluar an application thereof in the preparation of a drug for treating pneumonia.

Abstract: The present invention belongs to the field of microbiology, and particularly relates to membrane vesicles (MVs) isolated from bacteria, and an isolation and preparation system and method for the membrane vesicles, and applications of the membrane vesicles. The bacteria of the present invention comprise Gram-positive bacteria and Gram-negative bacteria. The invention uses ionizing irradiation to irradiate bacteria, and isolates and purifies the produced membrane vesicles. The membrane vesicles prepared can be used as a vaccine, a vaccine adjuvant and/or a pharmaceutical carrier. In addition, the present invention provides a biological composition comprising the membrane vesicles and inactivated bacteria. In addition, the present invention also provides a preparation system, and isolation and purification system for bacterial membrane vesicles and the corresponding method. The membrane vesicles obtained by using the system and method have high yield, high purity and easy to be industrialized.

Abstract: The present invention provides use of a Pseudomonas aeruginosa vaccine in the manufacture of a medicament for the prevention and treatment of respiratory system disease. The Pseudomonas aeruginosa vaccine of the present invention can effectively prevent and treat pulmonary infection caused by multidrug-resistant Pseudomonas aeruginosa and COPD complicated with Pseudomonas aeruginosa infection by activating the specific immune response of the body. The Pseudomonas aeruginosa vaccine of the present invention can reduce the bacterial load in the immunized subject through the established immunization procedures, thereby providing a technical solution that can effectively prevent pulmonary infection with Pseudomonas aeruginosa, which avoids the technical problems caused by the use of antibiotics such as poor effectiveness, difficulty in curing and proneness to drug resistance in the prior art to a certain degree.

Abstract: The present invention belongs to the field of microbiology, and particularly relates to an application of a Pseudomonas aeruginosa vaccine in prevention and treatment of burn and scald complicated with bacterial infection. The burn and scald of the present invention include burns and scalds, and degree of the scalds includes I degree, superficial II degree, deep II degree, or III degree scalds. Site of the scalds includes skin, mucosa or other tissues. The Pseudomonas aeruginosa vaccine of the present invention can effectively prevent and treat burn and scald complicated with Pseudomonas aeruginosa infection caused by multidrug-resistant Pseudomonas aeruginosa by activating the specific immune response of the body.

Abstract: The present invention relates to the field of tuberculosis vaccines, and specifically relates to a tuberculosis vaccine, a preparation method thereof, and a use thereof. To address the problem of existing vaccines being unsuitable for patients having weak immunity, the present invention provides a preparation method for a tuberculosis vaccine: first obtaining Mycobacterium single cell bacteria, and using low dosage radiation to irradiate periodically the Mycobacterium single cell bacteria, so as to obtain the tuberculosis vaccine. The present invention completely retains all of the antigen characteristics of the bacteria, and can more rapidly stimulate stronger specific immune responses, thereby achieving effective and long-lasting immunity. The vaccine prepared using the present invention has low toxicity, is rapid-acting and safer, and can be used for the prevention and treatment of tuberculosis for people having immunodeficiency.

Abstract: An application of a compound represented by formula (I) and pharmaceutically acceptable salts thereof in preparation of a drug for treating pneumonia.

Abstract: The present invention relates to the field of pharmaceutical preparations, in particular, to a mannose modified targeting nano-preparations, a composition for preparing nano-preparations, a targeting element, a targeting vector, a prepared targeting drug and a preparation method and the application thereof. The described nano-preparations with targeting function is composed of the targeting ligand mannose and its derivatives, nano-preparations and main drug components, and the described targeting material is linked with the spacer material, and then linked with the nano-preparations material to prepare the nano-preparations. The targeting nano-preparations in the present invention has good targetability of mannose receptor, can effectively bond with mannose receptor on target cell. Moreover, the preparation method has universality, can be used for synthesizing a variety of targeting nano-preparations, and is conducive to purification and characterization.

Abstract: Disclosed are a tumor biomarker and application thereof, and a tumor detection kit. Patients suffering from non-small cell lung cancer, containing an EML4-ALK or SLC34A2-ROS1 fusion gene, have a specific circular RNA in blood. The base sequences of the circular RNA are represented by SEQ ID NOS. 1-6. The circular RNA is associated with non-small cell lung cancer, stably and constantly exists in plasma samples, and has high specificity and effectiveness, and thus can be used as a biomarker for tumor detection. Reagents such as primers and probes for detecting the circular RNA can be used for preparing the tumor detection kit.